Complete financial analysis of Landec Corporation (LNDC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Landec Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Hongkong Land Holdings Limited (HNGKY) Income Statement Analysis – Financial Results
- NOVA Group Holdings Limited (1360.HK) Income Statement Analysis – Financial Results
- Emyria Limited (EMD.AX) Income Statement Analysis – Financial Results
- The Platform Group AG (TPG.DE) Income Statement Analysis – Financial Results
- Fawaz Abdulaziz Al Hokair & Company (4240.SR) Income Statement Analysis – Financial Results
Landec Corporation (LNDC)
About Landec Corporation
Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. Landec Corporation was incorporated in 1986 and is headquartered in Santa Maria, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 185.79M | 544.16M | 590.37M | 557.56M | 524.23M | 532.26M | 541.10M | 539.26M | 476.81M | 441.71M | 317.55M | 276.73M | 238.22M | 235.94M | 238.53M | 210.50M | 231.95M | 205.23M | 192.09M | 0.00 | 190.88M | 209.55M | 35.40M | 33.50M | 9.50M | 2.50M |
| Cost of Revenue | 135.42M | 462.69M | 515.38M | 476.56M | 445.89M | 449.07M | 470.14M | 473.85M | 414.25M | 378.95M | 265.41M | 230.03M | 204.46M | 201.66M | 200.30M | 178.11M | 191.91M | 173.26M | 162.30M | 0.00 | 163.30M | 170.12M | 19.30M | 18.20M | 5.10M | 500.00K |
| Gross Profit | 50.37M | 81.47M | 74.99M | 81.00M | 78.34M | 83.19M | 70.96M | 65.41M | 62.56M | 62.76M | 52.14M | 46.70M | 33.77M | 34.28M | 38.23M | 32.39M | 40.04M | 31.97M | 29.79M | 0.00 | 27.59M | 39.43M | 16.10M | 15.30M | 4.40M | 2.00M |
| Gross Profit Ratio | 27.11% | 14.97% | 12.70% | 14.53% | 14.94% | 15.63% | 13.11% | 12.13% | 13.12% | 14.21% | 16.42% | 16.87% | 14.17% | 14.53% | 16.03% | 15.39% | 17.26% | 15.58% | 15.51% | 0.00% | 14.45% | 18.82% | 45.48% | 45.67% | 46.32% | 80.00% |
| Research & Development | 7.84M | 10.22M | 11.10M | 11.47M | 12.80M | 9.47M | 7.23M | 6.99M | 7.20M | 9.29M | 9.63M | 9.28M | 4.36M | 3.67M | 3.25M | 3.07M | 3.04M | 2.54M | 3.73M | 0.00 | 3.27M | 4.70M | 5.80M | 5.70M | 7.60M | 3.80M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 46.13M | 65.36M | 72.19M | 64.06M | 51.95M | 55.63M | 49.52M | 39.96M | 35.17M | 32.53M | 26.52M | 24.61M | 17.70M | 18.02M | 19.80M | 21.62M | 27.98M | 23.41M | 22.00M | 0.00 | 26.97M | 28.88M | 11.20M | 10.80M | 4.70M | 3.30M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.93M | 1.42M | 4.78M | 0.00 | 0.00 | 0.00 | -22.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.07M | 2.20M | 2.10M | 1.10M | 500.00K |
| Operating Expenses | 53.97M | 75.59M | 83.29M | 75.53M | 64.75M | 65.10M | 56.74M | 46.95M | 42.37M | 37.89M | 37.56M | 38.66M | 22.06M | 21.68M | 23.05M | 2.02M | 31.02M | 25.96M | 25.74M | 0.00 | 30.24M | 39.64M | 19.20M | 18.60M | 13.40M | 7.60M |
| Cost & Expenses | 189.38M | 538.27M | 598.67M | 552.08M | 510.64M | 514.17M | 526.89M | 520.80M | 456.62M | 416.84M | 302.98M | 268.70M | 226.52M | 223.34M | 223.35M | 180.13M | 222.93M | 199.21M | 188.04M | 0.00 | 193.53M | 209.76M | 38.50M | 36.80M | 18.50M | 8.10M |
| Interest Income | 81.00K | 48.00K | 103.00K | 145.00K | 211.00K | 16.00K | 71.00K | 315.00K | 260.00K | 179.00K | 180.00K | 430.00K | 834.00K | 1.31M | 2.22M | 1.95M | 633.00K | 214.00K | 247.00K | 0.00 | 617.00K | 617.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 17.36M | 15.34M | 9.60M | 5.23M | 1.95M | 1.83M | 1.99M | 1.83M | 1.65M | 2.01M | 929.00K | 820.00K | 88.00K | 8.00K | -22.00K | -251.00K | -452.00K | -414.00K | -1.55M | 0.00 | -2.79M | -2.79M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 17.88M | 19.87M | 18.84M | 15.23M | 12.41M | 10.68M | 9.40M | 7.09M | 7.11M | 7.30M | 5.62M | 5.31M | 3.36M | 3.14M | 3.20M | 3.26M | 3.20M | 3.47M | 3.71M | 0.00 | 5.43M | 6.07M | 2.20M | 2.10M | 1.10M | 500.00K |
| EBITDA | -46.28M | -13.50M | -22.87M | 22.39M | 29.83M | 27.43M | -7.66M | 18.46M | 20.19M | 24.87M | 14.58M | 14.23M | 11.70M | 16.49M | 15.18M | 34.91M | 9.02M | 6.02M | 4.06M | 0.00 | -13.36M | 2.03M | -500.00K | -600.00K | -7.50M | -3.70M |
| EBITDA Ratio | -36.62% | -0.97% | -3.87% | 4.02% | 5.69% | 5.15% | -1.42% | 5.60% | 8.07% | 9.36% | 8.32% | 5.14% | 4.91% | 6.99% | 8.43% | 16.58% | 5.11% | 4.32% | 3.44% | 0.00% | -7.00% | 0.97% | -1.41% | -1.79% | -78.95% | -148.00% |
| Operating Income | -85.91M | -25.12M | -41.70M | 7.16M | 11.85M | 16.28M | -17.06M | 16.95M | 18.80M | 23.04M | 13.83M | 7.64M | 12.45M | 13.35M | 15.18M | 30.37M | 9.02M | 6.02M | 2.90M | 0.00 | -18.79M | -4.04M | -2.70M | -2.70M | -8.60M | -4.20M |
| Operating Income Ratio | -46.24% | -4.62% | -7.06% | 1.28% | 2.26% | 3.06% | -3.15% | 3.14% | 3.94% | 5.22% | 4.35% | 2.76% | 5.23% | 5.66% | 6.36% | 14.43% | 3.89% | 2.93% | 1.51% | 0.00% | -9.84% | -1.93% | -7.63% | -8.06% | -90.53% | -168.00% |
| Total Other Income/Expenses | -5.84M | -15.34M | -9.60M | -3.52M | 4.55M | -1.26M | -1.79M | 4.52M | 11.13M | 7.40M | 6.46M | 410.00K | -3.73M | -8.00K | 1.72M | 1.28M | -396.00K | -619.00K | 0.00 | 0.00 | 13.95M | 521.00K | 0.00 | 0.00 | 1.70M | 1.50M |
| Income Before Tax | -52.12M | -40.47M | -51.31M | 3.64M | 16.40M | 15.01M | -18.85M | 21.47M | 29.93M | 32.26M | 20.28M | 8.44M | 8.73M | 13.34M | 16.90M | 31.65M | 8.63M | 5.40M | 2.93M | 0.00 | -4.84M | -2.13M | -2.70M | -2.70M | -6.90M | -2.70M |
| Income Before Tax Ratio | -28.05% | -7.44% | -8.69% | 0.65% | 3.13% | 2.82% | -3.48% | 3.98% | 6.28% | 7.30% | 6.39% | 3.05% | 3.66% | 5.65% | 7.08% | 15.03% | 3.72% | 2.63% | 1.52% | 0.00% | -2.53% | -1.01% | -7.63% | -8.06% | -72.63% | -108.00% |
| Income Tax Expense | -5.84M | -7.80M | -13.12M | 1.52M | -9.36M | 4.34M | -7.40M | 7.75M | 10.58M | 9.45M | 7.19M | 4.18M | 4.26M | 5.61M | 3.35M | 2.46M | -24.00K | -4.00K | 29.00K | 0.00 | 3.04M | -42.00K | 100.00K | 200.00K | 1.70M | 1.50M |
| Net Income | -46.28M | -32.67M | -38.19M | 2.12M | 25.76M | 10.68M | -11.45M | 13.73M | 19.34M | 22.81M | 13.10M | 4.26M | 4.47M | 7.73M | 13.54M | 29.19M | 8.65M | 5.40M | 2.90M | 0.00 | -18.79M | -2.08M | -2.80M | -2.90M | -8.60M | -4.20M |
| Net Income Ratio | -24.91% | -6.00% | -6.47% | 0.38% | 4.91% | 2.01% | -2.12% | 2.55% | 4.06% | 5.16% | 4.12% | 1.54% | 1.87% | 3.28% | 5.68% | 13.87% | 3.73% | 2.63% | 1.51% | 0.00% | -9.84% | -0.99% | -7.91% | -8.66% | -90.53% | -168.00% |
| EPS | -1.57 | -1.11 | -1.31 | 0.07 | 0.92 | 0.39 | -0.42 | 0.51 | 0.72 | 0.86 | 0.51 | 0.16 | 0.17 | 0.30 | 0.52 | 1.16 | 0.35 | 0.23 | 0.14 | 0.00 | -1.15 | -0.13 | -0.21 | -0.23 | -0.77 | -0.55 |
| EPS Diluted | -1.57 | -1.11 | -1.31 | 0.07 | 0.92 | 0.39 | -0.42 | 0.50 | 0.71 | 0.86 | 0.50 | 0.16 | 0.17 | 0.29 | 0.50 | 1.10 | 0.34 | 0.22 | 0.12 | 0.00 | -1.15 | -0.13 | -0.21 | -0.22 | -0.77 | -0.55 |
| Weighted Avg Shares Out | 29.47M | 29.33M | 29.22M | 29.10M | 27.92M | 27.50M | 27.15M | 26.99M | 26.82M | 26.40M | 25.64M | 26.41M | 26.36M | 26.18M | 26.07M | 25.26M | 24.55M | 23.71M | 21.40M | 21.11M | 16.37M | 15.80M | 13.27M | 12.77M | 11.14M | 7.70M |
| Weighted Avg Shares Out (Dil) | 29.47M | 29.33M | 29.22M | 29.10M | 27.92M | 27.65M | 27.15M | 27.34M | 27.12M | 26.63M | 26.13M | 26.63M | 26.63M | 26.75M | 26.94M | 26.56M | 25.66M | 24.61M | 23.56M | 22.86M | 16.37M | 15.80M | 13.27M | 13.33M | 11.14M | 7.70M |
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
NEW YORK , May 13, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from...
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
NEW YORK , May 5, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from...
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
NEW YORK , April 29, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
NEW YORK , April 19, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from...
LFCR INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
NEW YORK , April 12, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from...
Landec Corporation (LNDC) Q1 2023 Earnings Call Transcript
Landec Corporation (NASDAQ:LNDC ) Q1 2023 Earnings Conference Call October 6, 2022 8:00 AM ET Company Participants Jeff Sonnek - Investor Relations, ICR Jim Hall - Chief Executive Officer John Morberg - Chief Financial Officer Conference Call Participants Jacob Johnson...
Landec (LNDC) Reports Q1 Loss, Tops Revenue Estimates
Landec (LNDC) delivered earnings and revenue surprises of -166.67% and 1.89%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Landec Corporation Revises First Quarter 2023 Earnings Conference Call for October 6, 2022 at 8:00 a.m. ET
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and...
Landec Corporation Sets First Quarter 2023 Earnings Conference Call for October 5, 2022 at 2:00 p.m. PT
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and...
7 Small-Cap Stocks to Buy Before September Ends
While broader markets face continued pressure amid recession fears, small-cap stocks stand out as an undervalued segment of the stock market. The Russell 2000 index, the popular benchmark for small-cap stocks, is currently down 18% over the past year.
Source: https://incomestatements.info
Category: Stock Reports